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An important component in making medical care decisions is risk prediction. Being able to accurately 
foretell the likelihood of an event, such as the appearance of a disease, based on predictive factors 
like biomarkers, age, sex, or family history of illness is becoming more and more common in health 
care. But how do we identify biomarkers that would improve upon current models used for risk 
prediction? Since 2008, the net risk reclassification index (NRI), a method for measuring the 
usefulness of adding a new biomarker or set of biomarkers to a current risk prediction model, has 
been widely used. However, a recent study carried out by Drs. Margaret Pepe, Holly Janes, and 
Christopher Li of the Public Health Sciences Division questions the validity of this method for 
assigning importance to new biomarkers. Their study was published in the Journal of the National 
Cancer Institute. 
The NRI was devised as an alternative to the traditional way of determining the usefulness of a new 
biomarker for improving risk prediction. Previously, researchers considered the improvement in the 
area under the receiver operating characteristic curve (ΔAUC), a statistical measure of 
discrimination, when a new biomarker was added to the original risk model. However, promising new 
biomarkers often failed to produce large increases in the area under the curve. The alternative 
method, the NRI, is based on combining probabilities for increases in predicted risks for subjects 
who have events together with decreases in predicted risks for subjects who do not have events, 
both scenarios that are favorable for a biomarker. In the six years since its introduction, the NRI has 
gained traction in research, particularly in cardiovascular research, but also increasingly in cancer 
research publications. "In 2013 alone, the statistic appeared in almost 600 papers including papers 
published in the most prestigious medical journals," said Dr. Pepe, lead author of the study. Despite 
its growth in popularity, it was not fully known whether the NRI truly was a robust method for 
assigning importance to biomarkers correctly. 
Dr. Pepe and co-workers chose to test the NRI method by performing simulated studies on an 
already existing dataset. They utilized a population dataset of 10,000 individuals with an event rate 
of 10.2%. They chose four biomarkers with no predictive ability and repeatedly calculated the NRI on 
a randomly chosen subset of patients to test for a positive statistically significant result. The rate of 
these false-positive results would be expected to be approximately 5.0%, based on the definition of 
statistical significance. Upon performing 5000 simulations, the rate at which the NRI generated a 
false-positive result was 63%, 23% or 34% depending on the dataset chosen for calculating the NRI. 
This finding was quite alarming. Dr. Pepe explained, "Our results show that positive conclusions 
based on the NRI statistic are quite likely to be false even in very well designed biomarker studies." 
It is worrisome that a methodology of such high prevalence in the research community would be 
found to be so error-prone. Hopefully, the NRI is only an outlier and not representative of other 
common statistical metrics. Dr. Pepe believes that, "For the most part statistical methodology is 
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evaluated rigorously before being applied routinely to real data," and that, "Somehow this invalid 
methodology based on the NRI statistic slipped in between the cracks." 
There is a lesson to be learned here. According to Dr. Pepe, "this occurrence reminds us to always 
critically examine the fundamentals and to not take for granted that some procedure works just 
because we expect it to. That statement of course applies to all of science, not just to statistical 
procedures." 
The important direct conclusion to be drawn from the study is the invalidation of the NRI. "The 
implication of our paper is that scientists should not use the NRI statistic for evaluating biomarkers. 
Moreover, readers and reviewers must be skeptical about the results of biomarker studies that 
indicate good biomarker performance based primarily on statistical significance of the NRI statistic," 
said Dr. Pepe. 
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Image provided by Dr. Margaret Pepe. 
Chance of a false-positive conclusion for four useless biomarkers when using the Net 
Reclassification Index (NRI) statistic p-value. A training set of 420 subjects of whom 10% had events 
were used to fit risk models with and without the biomarkers. The expected rate of false-positive 
conclusions due to random chance is 5%, but the actual rates are much higher. 
 
